期刊文献+

HPLC-MS/MS测定血浆中的丙戊酸镁及其大鼠体内药动学研究 被引量:2

Determination of Magnesium Valprote in Plasma by HPLC-MS/MS Method and Its Pharmacokinetics in Rats
原文传递
导出
摘要 目的建立高效液相色谱-质谱/质谱联用法(HPLC-MS/MS)测定人血浆中丙戊酸镁的方法,并用于大鼠药动学研究。方法采用Shim-pack XR-ODS柱(3.0 mm×75 mm),柱温25℃,流动相A为0.1%甲酸水溶液,B为甲醇,洗脱梯度为0-1.0 min 80%B,80%B平衡1.0-5.0 min;流速0.4 mL.min-1;用正离子电喷雾电离源,多反应方式检测,丙戊酸镁用于定量分析的离子对为m/z312.4→m/z102.2。血浆样品用甲醇沉淀蛋白后进样。结果丙戊酸镁在6.25-4 000 ng.mL-1线性关系良好,相关系数为0.995 9,最低定量限为6.25 ng.mL^-1。加样回收率94.88%-97.62%,日内日间精密度RSD均小于12%。丙戊酸镁缓释片起效慢,作用力维持时间比丙戊酸镁片长。结论该方法分析速度快、操作简单、灵敏度高,适用于丙戊酸镁药动学研究。 OBJECTIVE To establish a HPLC-MS/MS method for the determination of magnesium valprote in rat plasma and to study the pharmacokinetics of magnesium valprote.METHODS The analytes were determined by HPLC-MS/MS method using Shim-pack XR-ODS column.The mobile phase was composed by 0.1% formic acid and methanol.The analysis was achieved with gradient elution and positive ion MRM detection of magnesium valprote(m/z 312.4→102.2).The column temperature was at 25 ℃.The plasma was deproteinized with methanol directly.RESULTS The calibration curve was linear within 6.25-4 000 ng·mL-1(r=0.995 9).The lower limit of quantitation was 6.25 ng·mL-1.The recovery was in the range of 94.88%-97.62%.The relative standard deviations for the intra-day and inter-day validation were less than 12%.The pharmacokinetic parameters were calculated as the follows: ρmax(2 608.33±83.86) ng·mL-1;tmax(7.00±1.73) h;t1/2(27.99±1.52) h;AUC0-96(97 858.06±4 157.10) ng·h·mL-1;AUC0-∞(108 733.06±6 598.60) ng·h·mL-1 of magnesium valprote in rats.CONCLUSION The method is simple,accurate,fast,sensitive and suitable for the pharmacokinetic study of magnesium valprote.
出处 《中国药学杂志》 CAS CSCD 北大核心 2011年第5期378-381,共4页 Chinese Pharmaceutical Journal
基金 国家科技部重大资助项目(2008ZXJ09014-010)
关键词 丙戊酸镁 高效液相色谱质谱联用法 药动学 大鼠 magnesium valprote HPLC-MS/MS pharmacokinetics rat
  • 相关文献

参考文献6

二级参考文献16

  • 1姜德春,王丽.丙戊酸钠的群体药代动力学[J].儿科药学杂志,2004,10(3):7-9. 被引量:9
  • 2邹远高,秦永平,余勤,梁茂植.气相色谱法测定血清中丙戊酸钠浓度[J].华西医学,1994,9(4):413-415. 被引量:4
  • 3陈新悦.丙戊酸钠的临床新用途[J].中国药业,2006,15(10):62-62. 被引量:3
  • 4李家泰.临床药理学[M].北京:人民卫生出版社,1997.901-902.
  • 5黄希顺 唐敦立.丙戊酸类药物的药理与临床[M].郑州:河南医科大学出版社,1996.28-110.
  • 6[1]Wang L, Wang XD. Pharmacodinetic and pharmacodynamic effects of clonazepam in children with epilepsy rreated with valproate: a preliminary study[J]. Ther Drug Monit, 2002,24(4):32~36.
  • 7[2]Franke G, Diletti E, Hoffmann C,et al. Relative bioavailability of different valproic acid formulations[J]. Int J Clin Pharmacos Ther, 1995,33(12):653~657.
  • 8肖波.癫痫的心理治疗和健康指导.新药和业界新闻,2005,:10-68.
  • 9黄希顺,朱延明,胡合树,等.癫痫防治240问(修订版)[M].北京:金盾出版社,1994:109.
  • 10刘福清,吴月萍,付汝仁.小儿血清中丙戊酸钠含量测定[J].中国医院药学杂志,1990,10(2):76-78. 被引量:6

共引文献65

同被引文献31

  • 1崔一民,孙培红,刘玉旺,赵侠,李荣,孙忠民.高效液相色谱-荧光检测法测定人血清中丙戊酸钠浓度[J].中国药房,2005,16(4):286-288. 被引量:20
  • 2全向阳,陈颖,陈波,刘起军,朱墨,束家有.HPLC-ELSD法测定银杏叶分散片中萜类内酯的溶出度[J].中国药师,2006,9(8):708-711. 被引量:5
  • 3王亚敏.浅谈溶出度检查方法的研究[J].药物分析杂志,2007,27(10):1667-1670. 被引量:28
  • 4TERBACH N, WILLIAMS R S. Structure-function studies for the panacea, valproic acid[J]. Biochem Soc Trans, 2009, 37(5) : 1126-1132.
  • 5NANAU R M, NEUMAN M G. Adverse drug reactions induced by valproic acid[J]. Clin Biochem, 2013, 46(15) :1323-1338.
  • 6SCHMID M M, FREUDENMANN R W, KELLER F, et al. Non-fa- tal and fatal liver failure associated with valproic acid [J]. Pharma- copsychiatry, 2013, 46(2) :63-68.
  • 7CHANG T K H, ABBOTY F S. Oxidative stress as a mechanism of valproic acid associated hepatotoxicity [ J ]. Drug Metab Rev, 2006, 38(4) :627-639.
  • 8KIANG T K L, HOP C, ANARI M R, et al. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9 * 1/* 1 genotype[J]. Toxicol Sci, 2006, 94(2) :261-271.
  • 9LEE S, LEE J, KIM J, et al. The relationship between glucu- ronide conjugate levels and hepatotoxicity after oral administration of valproie acid[ J]. Arch Pharm Res, 2009,32(7 ) : 1029-1035.
  • 10CHEM Z J,WANG X D,WANG H S, et al. Simultaneous deter- mination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epi-lepsy[J]. Seizure, 2012, 21(2) :110-117.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部